Cessation and reduction in alcohol consumption and misuse after psychedelic use
An anonymous online survey of 343 mostly White male adults with prior severe AUD found that a single naturalistic moderate-to-high dose psychedelic experience (primarily LSD or psilocybin) was associated with marked reductions or cessation in alcohol use, with 83% no longer meeting AUD criteria afterwards. Greater dose and higher ratings of mystical-type, insightful and personally meaningful effects predicted larger reductions, though causality cannot be established and the findings support further clinical investigation of psychedelic-assisted treatment for AUD.
Authors
- Albert Garcia-Romeu
- Roland Griffiths
- Matthew Johnson
Published
Abstract
Background
Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders.
Aims
To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use.
Methods
An anonymous online survey of individuals with prior AUD reporting cessation or reduction in alcohol use following psychedelic use in non-clinical settings.
Results
343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting retrospective criteria for severe AUD. Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption. After the psychedelic experience 83% no longer met AUD criteria. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced alcohol misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress.
Conclusions
Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.
Research Summary of 'Cessation and reduction in alcohol consumption and misuse after psychedelic use'
Introduction
Garcia-Romeu and colleagues frame the study within a context of high prevalence and poor treatment uptake for alcohol use disorder (AUD), noting limitations of current pharmacotherapies and psychosocial interventions, including high relapse rates. Earlier clinical research from the mid-20th century and recent pilot studies suggest that classic serotonergic psychedelics (notably LSD and psilocybin) may reduce problematic alcohol use; particular subjective qualities of the drug experience (for example, mystical-type effects and psychological insight) have been proposed as processes that might facilitate lasting behaviour change. This study set out to systematically characterise instances in which naturalistic (nonclinical) psychedelic use was followed by self-reported cessation or reduction in alcohol misuse. Using an anonymous online survey, the investigators sought to describe participant characteristics, the psychedelic experiences implicated, changes in alcohol use and related symptoms, and associations between psychedelic experience features (dose, mystical and insightful qualities, persisting personal meaning) and changes in alcohol consumption. The authors hypothesised that greater mystical-type subjective qualities would be associated with larger reductions in alcohol use.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088-1101. https://doi.org/10.1177/0269881119845793
References (61)
Papers cited by this study that are also in Blossom
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)
Bonson, K. R. · Psychopharmacology (2017)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Berro, L. F., Marinho, E. A. V., Cata-Preta, E. G. et al. · Frontiers in Pharmacology (2018)
Davis, A. K., Barsuglia, J. P., Lancelotta, R. et al. · Journal of Psychopharmacology (2018)
Show all 61 referencesShow fewer
Doblin, R. · Journal of Transpersonal Psychology (1991)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Dyck, E. · Social History of Medicine (2006)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)
Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Sessa, B. · Neuropharmacology (2017)
Sessa, B., Johnson, M. W. · British Journal of Psychiatry (2018)
Spitzer, M., Thimm, M., Hermle, L. et al. · Biological Psychiatry (1996)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Tomsovic, M., Edwards, R. V. · Journal of Studies on Alcohol and Drugs (1970)
Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)
Cited By (89)
Papers in Blossom that reference this study
Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)
Cherniak, A. D., Granqvist, P., Mikulincer, M. et al. · Journal of Psychoactive Drugs (2026)
Fabiano, N., Stubbs, B., Lawrence, D. W. et al. · Discover Mental Health (2026)
Marsden, J., Kelleher, M., Dunbar, F. et al. · Addiction (2025)
Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)
Bonomo, Y. A., Norman, A. F., Collins, L. et al. · Frontiers in Psychiatry (2025)
Teixeira, P. J., Jain, R., Penn, A. D. et al. · Preventative Medicine Reports (2025)
Kugel, J., Laukkonen, R., Yaden, D. B. et al. · Neuroscience and Biobehavioral Reviews (2025)
Gumpper, R. H., Jain, M. K., Kim, K. et al. · Nature Communications (2025)
Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)
Show all 89 papersShow fewer
Anderson, T. L., Keady, J. V., Songrady, J. et al. · Progress in Neurobiology (2024)
McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)
Bagdasarian, F. A., Hansen, H. D., Chen, J. et al. · ACS Chemical Neuroscience (2024)
Moreton, S. G., Barr, N., Giese, K. J. · Death Studies (2024)
Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Cherniak, A. D., Mikulincer, M., Brulin, J. G. et al. · Journal of Psychedelic Studies (2024)
Tap, S. C. · Addiction Biology (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Agin-Liebes, G. I., Nielson, E. M., Zingman, M. et al. · Psychology of Addictive Behaviors (2024)
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Mortaheb, S., Fort, L. D., Mason, N. L. et al. · Biological Psychiatry (2023)
Buot, A., Pallares, C., Oganesyan, A. et al. · Scientific Reports (2023)
Romeo, B., Fauvel, B., Verroust, V. et al. · Journal of Psychoactive Drugs (2023)
Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)
Lake, S., Lucas, P. · Psychedelic Medicine (2023)
Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)
Kangaslampi, S. · Journal of Psychedelic Studies (2023)
Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)
Kaup, K. K., Vasser, M., Tulver, K. et al. · Frontiers in Psychiatry (2023)
Nikolaidis, A., Lancelotta, R., Gukasyan, N. et al. · Journal of Affective Disorders (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Armstrong, S. B., Xin, Y., Sepeda, N. D. et al. · Military Medicine (2023)
Olsen, A. S., Ozenne, B., Madsen, M. K. et al. · NeuroImage (2022)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Therapeutic Advances in Psychopharmacology (2022)
Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)
Madsen, M. K., Ozenne, B., Armand, S. et al. · Frontiers in Psychology (2022)
Hendricks, P. S., Simonsson, O. · Journal of Psychopharmacology (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Mellner, C., Dahlen, M., Simonsson, O. · International Journal of Environmental Research and Public Health (2022)
Luoma, J. B., Pilecki, B., Davis, A. K. et al. · Drugs Education Prevention and Policy (2022)
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)
Fadahunsi, N., Lund, J., Breum, A. W. et al. · Translational Psychiatry (2022)
Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)
Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)
Johnson, M. W. · Current Topics in Behavioral Neurosciences (2022)
Basedow, L. A., Kuitunen-Paul, S. · Drug and Alcohol Review (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Jones, G. M., Nock, M. K. · Scientific Reports (2022)
Mangini, P., Averill, L. A., Davis, A. K. · Journal of Psychedelic Studies (2022)
Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Niles, H., Fogg, C., Kelmendi, B. et al. · BMC Palliative Care (2021)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)
Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Mayer, C. E., LeBaron, V. T., Acquaviva, K. D. · Journal of Psychoactive Drugs (2021)
Healy, C. J., Lee, K. A. · Chronic Stress (2021)
Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)
Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Rush, B., Marcus, O., García, S. et al. · Frontiers in Pharmacology (2021)
Uthaug, M. V., Davis, A. K., Davis, D. et al. · Journal of Psychopharmacology (2021)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Smith, W. R., Sisti, D. · Journal of Medical Ethics (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Lancelotta, R., Davis, A. K. · Journal of Psychoactive Drugs (2020)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.